Arcutis Biotherapeutics (ARQT)
(Delayed Data from NSDQ)
$8.47 USD
-0.12 (-1.40%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $8.45 -0.02 (-0.24%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth B Momentum F VGM
Income Statements
Fiscal Year end for Arcutis Biotherapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 60 | 4 | 0 | 0 | 0 |
Cost Of Goods | 5 | 1 | 0 | 0 | 0 |
Gross Profit | 55 | 3 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 296 | 305 | 207 | 137 | 43 |
Income After Depreciation & Amortization | -241 | -302 | -207 | -137 | -43 |
Non-Operating Income | 12 | 6 | 0 | 1 | 1 |
Interest Expense | 30 | 16 | 0 | 0 | 0 |
Pretax Income | -259 | -311 | -206 | -136 | -42 |
Income Taxes | 3 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -262 | -311 | -206 | -136 | -42 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -262 | -311 | -206 | -136 | -42 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -247 | -303 | -203 | -136 | -43 |
Depreciation & Amortization (Cash Flow) | -5 | -1 | 4 | 0 | 0 |
Income After Depreciation & Amortization | -241 | -302 | -207 | -137 | -43 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 69.31 | 55.03 | 49.41 | 35.67 | 1.84 |
Diluted EPS Before Non-Recurring Items | -3.78 | -5.66 | -4.18 | -3.80 | -22.78 |
Diluted Net EPS (GAAP) | -3.78 | -5.66 | -4.18 | -3.80 | -22.78 |
Fiscal Year end for Arcutis Biotherapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 13.53 | 38.11 | 5.19 | 2.78 |
Cost Of Goods | NA | 2.25 | 1.18 | 0.78 | 0.78 |
Gross Profit | NA | 11.28 | 36.93 | 4.41 | 2.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 72.44 | 73.84 | 71.18 | 78.27 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -61.16 | -36.91 | -66.77 | -76.27 |
Non-Operating Income | NA | 2.74 | 2.72 | 3.12 | 3.21 |
Interest Expense | NA | 7.76 | 7.56 | 7.35 | 7.04 |
Pretax Income | NA | -66.19 | -41.74 | -70.99 | -80.10 |
Income Taxes | NA | 0.09 | 3.02 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -66.28 | -44.77 | -70.99 | -80.10 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -66.28 | -44.77 | -70.99 | -80.10 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 92.58 | 61.73 | 61.43 | 61.17 |
Diluted EPS Before Non-Recurring Items | NA | -0.72 | -0.73 | -1.16 | -1.31 |
Diluted Net EPS (GAAP) | NA | -0.58 | -0.73 | -1.16 | -1.31 |